Targeting the DNA damage response in oncology: past, presen... : Current Opinion in Oncology
Current Opinion in Oncology:
May 2012 - Volume 24 - Issue 3 - p 316–324
doi: 10.1097/CCO.0b013e32835280c6
INNOVATIVE EARLY CLINICAL TRIALS METHODOLOGY AND NEW THERAPEUTICS IN CANCER: Edited by Ahmad Awada
Targeting the DNA damage response in oncology: past, present and future perspectives
Abstract
Purpose of review:
The success of poly(ADP-ribose)
polymerase inhibition in BRCA1 or BRCA2 deficient tumors as an
anticancer strategy provided proof-of-concept for a synthetic lethality
approach in oncology. There is therefore now active interest in
expanding this approach to include other agents targeting the DNA damage
response (DDR). We review lessons learnt from the development of
inhibitors against DNA damage response mechanisms and envision the
future of DNA repair inhibition in oncology.
